{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T00:03:27Z","timestamp":1791072207407,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,23]],"date-time":"2023-12-23T00:00:00Z","timestamp":1703289600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004203","name":"Ontario Institute for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004203","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.radonc.2023.110070","type":"journal-article","created":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T17:04:00Z","timestamp":1705943040000},"page":"110070","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Using multiparametric Magnetic Resonance Imaging and Prostate Specific Membrane Antigen Positron Emission Tomography to detect and delineate the gross tumour volume of intraprostatic lesions \u2013 A systematic review and meta-analysis"],"prefix":"10.1016","volume":"192","author":[{"given":"Aneesh","family":"Dhar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose de Jesus","family":"Cendejas-Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"Castro Mendez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Boldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"McArthur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantinos","family":"Zamboglou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn","family":"Bauman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2023.110070_b0005","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.radonc.2023.110070_b0010","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2214122","article-title":"Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer","author":"Hamdy","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2023.110070_b0015","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/j.ijrobp.2020.07.2194","article-title":"An updated analysis of survival endpoints for ASCENDE-RT, a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost for high-and intermediate-risk prostate cancer","volume":"108","author":"Oh","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.110070_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2022.07.011","article-title":"Local failure events in prostate cancer treated with radiotherapy: a pooled analysis of 18 randomized trials from the meta-analysis of randomized trials in cancer of the prostate consortium (leviathan)","author":"Ma","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.radonc.2023.110070_b0025","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0360-3016(02)02795-5","article-title":"Analysis of intraprostatic failures in patients treated with hormonal therapy and radiotherapy: implications for conformal therapy planning","volume":"53","author":"Cellini","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.110070_b0030","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1200\/JCO.20.02873","article-title":"Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: Results from the FLAME randomized phase III trial","volume":"39","author":"Kerkmeijer","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2023.110070_b0035","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2023.110070_b0040","first-page":"1644","article-title":"The PRIMARY Score: Using Intraprostatic 68Ga-PSMA PET\/CT patterns to optimize prostate cancer diagnosis","volume":"63","author":"Emmett","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.radonc.2023.110070_b0045","doi-asserted-by":"crossref","unstructured":"Nandurkar R, Van Leeuwen P, Stricker P, Woo H, Kooner R, Yuen C, O'Neill G, Ende D, Cusick T, Ho B, Hickey A. 68Ga-HBEDD PSMA-11 PET\/CT staging prior to radical prostatectomy in prostate cancer patients: Diagnostic and predictive value for the biochemical response to surgery. The British journal of radiology. 2019 Mar;92:20180667. https:\/\/doi.org\/10.1259%2Fbjr.20180667.","DOI":"10.1259\/bjr.20180667"},{"key":"10.1016\/j.radonc.2023.110070_b0050","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.ijrobp.2022.04.020","article-title":"PSMA-PET-and MRI-based focal dose escalated radiation therapy of primary prostate cancer: Planned safety analysis of a nonrandomized 2-armed phase 2 trial (ARO2020-01)","volume":"113","author":"Zamboglou","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.110070_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijsu.2021.105906","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"88","author":"Page","year":"2021","journal-title":"Int J Surg"},{"key":"10.1016\/j.radonc.2023.110070_b0060","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.eururo.2019.02.033","article-title":"Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2","volume":"76","author":"Turkbey","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.radonc.2023.110070_b0065","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1038\/bjc.2013.185","article-title":"A step-by-step guide to the systematic review and meta-analysis of diagnostic and prognostic test accuracy evaluations","volume":"108","author":"Liu","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.radonc.2023.110070_b0070","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.3348\/kjr.2015.16.6.1188","article-title":"Systematic review and meta-analysis of studies evaluating diagnostic test accuracy: a practical review for clinical researchers-part II. Statistical methods of meta-analysis","volume":"16","author":"Lee","year":"2015","journal-title":"Korean J Radiol"},{"key":"10.1016\/j.radonc.2023.110070_b0075","first-page":"15","article-title":"Meta-analysis of diagnostic accuracy with mada","volume":"1","author":"Doebler","year":"2015","journal-title":"R Packag"},{"key":"10.1016\/j.radonc.2023.110070_b0080","doi-asserted-by":"crossref","unstructured":"Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, Leeflang MM, Sterne JA, Bossuyt PM, QUADAS-2 Group*. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Annals of internal medicine. 2011 Oct 18;155:529-36. https:\/\/doi.org\/10.7326\/0003-4819-155-8-201110180-00009.","DOI":"10.7326\/0003-4819-155-8-201110180-00009"},{"key":"10.1016\/j.radonc.2023.110070_b0085","doi-asserted-by":"crossref","unstructured":"Yang B, Mallett S, Takwoingi Y, Davenport CF, Hyde CJ, Whiting PF, Deeks JJ, Leeflang MM, QUADAS-C Group\u2020. QUADAS-C: a tool for assessing risk of bias in comparative diagnostic accuracy studies. Annals of internal medicine. 2021 Nov;174:1592-9. https:\/\/doi.org\/10.7326\/M21-2234.","DOI":"10.7326\/M21-2234"},{"key":"10.1016\/j.radonc.2023.110070_b0090","doi-asserted-by":"crossref","first-page":"5836","DOI":"10.1038\/s41598-021-85028-5","article-title":"The impact of the co-registration technique and analysis methodology in comparison studies between advanced imaging modalities and whole-mount-histology reference in primary prostate cancer","volume":"11","author":"Zamboglou","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.radonc.2023.110070_b0095","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.radonc.2019.07.005","article-title":"[68Ga-] PSMA-11 PET\/CT and multiparametric MRI for gross tumor volume delineation in a slice by slice analysis with whole mount histopathology as a reference standard\u2013Implications for focal radiotherapy planning in primary prostate cancer","volume":"141","author":"Bettermann","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2023.110070_b0100","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1148\/radiol.2018180788","article-title":"Diagnostic accuracy of 68Ga-PSMA-11 PET\/MRI compared with multiparametric MRI in the detection of prostate cancer","volume":"289","author":"Hicks","year":"2018","journal-title":"Radiology"},{"key":"10.1016\/j.radonc.2023.110070_b0105","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/bju.14794","volume":"124","author":"Scheltema","year":"2019","journal-title":"BJU Int"},{"key":"10.1016\/j.radonc.2023.110070_b0110","doi-asserted-by":"crossref","first-page":"847","DOI":"10.2967\/jnumed.121.262398","volume":"63","author":"Sonni","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.radonc.2023.110070_b0115","doi-asserted-by":"crossref","first-page":"228","DOI":"10.7150\/thno.16638","article-title":"Comparison of 68Ga-HBED-CC PSMA-PET\/CT and multiparametric MRI for gross tumour volume detection in patients with primary prostate cancer based on slice by slice comparison with histopathology","volume":"7","author":"Zamboglou","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.radonc.2023.110070_b0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1745-6215-12-255","article-title":"Single blind randomized phase III trial to investigate the benefit of a focal lesion ablative microboost in prostate cancer (FLAME-trial): study protocol for a randomized controlled trial","volume":"12","author":"Lips","year":"2011","journal-title":"Trials"},{"key":"10.1016\/j.radonc.2023.110070_b0125","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.radonc.2020.03.015","article-title":"Primary endpoint analysis of the multicentre phase II hypo-FLAME trial for intermediate and high risk prostate cancer","volume":"147","author":"Draulans","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2023.110070_b0130","first-page":"88","article-title":"Stereotactic radiotherapy with focal boost for intermediate and high-risk prostate cancer: Initial results of the SPARC trial","volume":"25","author":"Nicholls","year":"2020","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.radonc.2023.110070_b0135","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.ijrobp.2022.09.058","article-title":"Standard and hypofractionated dose escalation to intraprostatic tumor nodules in localized prostate cancer: 5-Year efficacy and toxicity in the DELINEATE trial","volume":"115","author":"Tree","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.110070_b0140","first-page":"22","article-title":"PIVOTALboost: A phase III randomised controlled trial of prostate and pelvis versus prostate alone radiotherapy with or without prostate boost (CRUK\/16\/018)","volume":"25","author":"Syndikus","year":"2020","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.radonc.2023.110070_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109503","article-title":"Two-fraction stereotactic ablative radiotherapy with simultaneous boost to MRI-defined dominant intra-prostatic lesion\u2013Results from the 2SMART phase 2 trial","volume":"181","author":"Ong","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2023.110070_b0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13014-022-02173-5","article-title":"Focal HDR brachytherapy boost to stereotactic radiotherapy (fBTsRT) for prostate cancer: a phase II randomized controlled trial","volume":"17","author":"Belliveau","year":"2022","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2023.110070_b0155","article-title":"Imaging biomarkers in prostate stereotactic body radiotherapy: A review and clinical trial protocol","volume":"12","author":"Liu","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.radonc.2023.110070_b0160","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.ijrobp.2022.04.020","article-title":"PSMA-PET-and MRI-based focal dose escalated radiation therapy of primary prostate cancer: Planned safety analysis of a nonrandomized 2-armed phase 2 trial (ARO2020-01)","volume":"113","author":"Zamboglou","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.110070_b0165","doi-asserted-by":"crossref","first-page":"5795","DOI":"10.3390\/cancers13225795","article-title":"PSMA-PET\/MRI-based focal dose escalation in patients with primary prostate Cancer treated with stereotactic body radiation therapy (HypoFocal-SBRT): study protocol of a randomized, multicentric phase III trial","volume":"13","author":"Zamboglou","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.radonc.2023.110070_b0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13014-018-1014-1","article-title":"The dose distribution in dominant intraprostatic tumour lesions defined by multiparametric MRI and PSMA PET\/CT correlates with the outcome in patients treated with primary radiation therapy for prostate cancer","volume":"13","author":"Zamboglou","year":"2018","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2023.110070_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109774","article-title":"Deep learning based automated delineation of the intraprostatic gross tumour volume in PSMA-PET for patients with primary prostate cancer","volume":"188","author":"Holzschuh","year":"2023","journal-title":"Radiother Oncol"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814023093775?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814023093775?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T05:28:32Z","timestamp":1759123712000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814023093775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":35,"alternative-id":["S0167814023093775"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2023.110070","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Using multiparametric Magnetic Resonance Imaging and Prostate Specific Membrane Antigen Positron Emission Tomography to detect and delineate the gross tumour volume of intraprostatic lesions \u2013 A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2023.110070","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"110070"}}